Sulanemadlin

N/A

Report date: 2025/04/20 20:00:03
NME

Base Information

Drug NameSulanemadlin
Drug Alias NameALRN-6924
ClassificationSmall molecules > Synthetic peptide
Mechanisms of Actionp53-binding protein Mdm-2 inhibitorsProtein Mdm4 inhibitors
Targetsp53-binding protein Mdm-2Protein Mdm4
Therapy Area/IndicationsSolid tumoursChemotherapy-induced myelosuppressionMyelodysplastic Syndromes +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBosnia and HerzegovinaBulgariaUnited States +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesRein Therapeutics IncF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteAdvancium Health NetworkThe University Of Texas MD Anderson Cancer Center +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursBrain NeoplasmsBreast Neoplasms +[5] 
Inactive IndicationsChemotherapy-induced myelosuppressionMyelodysplastic SyndromesSmall Cell Lung Carcinoma +[6] 

Other Information

ATC CodeN/A
Related LinksN/A